Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar and Icotinib in Advanced NSCLC With EGFR Mutations
NCT02375022Phase 2Unknown
- Sponsor
- Zhejiang University
- Start
- Mar 2015
- Primary completion
- Mar 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in non-small cell lung cancer (NSCLC), sponsored by Zhejiang University. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02375022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375022.